Genomic alterations distinct for black men with prostate cancer

Genomic alterations distinct for black men with prostate cancer

(HealthDay)—African-American (AFR) men with prostate cancer have distinct genomic alterations from European-American (EUR) men, according to a study published online July 10 in Clinical Cancer Research.

Yusuke Koga, from the Boston University School of Medicine, and colleagues compared the frequencies of somatic alterations in prostate obtained from four datasets comprising 250 AFR and 611 EUR men and a targeted sequencing dataset from a commercial platform of 436 AFR men and 3,018 EUR men. The authors sought to examine genomic alterations associated with race.

The researchers found that in tumors from AFR men, mutations in ZFHX3 and focal deletions in ETV3 were more frequent. There was an association for TP53 mutations with increasing Gleason score. Tumors from AFR men with more often had MYC amplifications, while tumors from AFR less frequently had deletions in PTEN and rearrangements in TMPRSS2-ERG. Primary from AFR men more often had KMT2D truncations and CCND1 amplifications. There was no significant difference noted between the two groups in genomic features that could impact clinical decision-making, including tumor burden, microsatellite instability status, and in select DNA repair genes, CDK12, and in AR.

"The genomic differences seen in genes such as MYC, ZFHX3, PTEN, and TMPRSS2-ERG suggest that different pathways of carcinogenesis may be active in AFR men, which could lead to further disparities if targeted therapies for some of these alterations become available," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further

Largest study of prostate cancer genomics in Black Americans IDs targets for therapies

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Clinical Cancer Research

Copyright © 2020 HealthDay. All rights reserved.

Citation: Genomic alterations distinct for black men with prostate cancer (2020, July 14) retrieved 19 April 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments